1. Home
  2. AVDL vs ETD Comparison

AVDL vs ETD Comparison

Compare AVDL & ETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • ETD
  • Stock Information
  • Founded
  • AVDL 2015
  • ETD 1932
  • Country
  • AVDL Ireland
  • ETD United States
  • Employees
  • AVDL N/A
  • ETD N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • ETD Home Furnishings
  • Sector
  • AVDL Health Care
  • ETD Consumer Discretionary
  • Exchange
  • AVDL Nasdaq
  • ETD Nasdaq
  • Market Cap
  • AVDL 784.6M
  • ETD 709.8M
  • IPO Year
  • AVDL 1996
  • ETD 1993
  • Fundamental
  • Price
  • AVDL $8.03
  • ETD $26.51
  • Analyst Decision
  • AVDL Strong Buy
  • ETD Hold
  • Analyst Count
  • AVDL 7
  • ETD 2
  • Target Price
  • AVDL $18.86
  • ETD $32.00
  • AVG Volume (30 Days)
  • AVDL 1.1M
  • ETD 326.1K
  • Earning Date
  • AVDL 05-07-2025
  • ETD 05-05-2025
  • Dividend Yield
  • AVDL N/A
  • ETD 5.89%
  • EPS Growth
  • AVDL N/A
  • ETD N/A
  • EPS
  • AVDL N/A
  • ETD 2.39
  • Revenue
  • AVDL $169,117,000.00
  • ETD $626,650,000.00
  • Revenue This Year
  • AVDL $50.53
  • ETD N/A
  • Revenue Next Year
  • AVDL $32.33
  • ETD $2.47
  • P/E Ratio
  • AVDL N/A
  • ETD $11.09
  • Revenue Growth
  • AVDL 504.79
  • ETD N/A
  • 52 Week Low
  • AVDL $6.38
  • ETD $24.55
  • 52 Week High
  • AVDL $19.09
  • ETD $35.62
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 54.47
  • ETD 46.33
  • Support Level
  • AVDL $6.38
  • ETD $25.77
  • Resistance Level
  • AVDL $8.22
  • ETD $27.39
  • Average True Range (ATR)
  • AVDL 0.48
  • ETD 1.34
  • MACD
  • AVDL 0.11
  • ETD -0.02
  • Stochastic Oscillator
  • AVDL 89.67
  • ETD 55.21

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About ETD Ethan Allen Interiors Inc.

Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.

Share on Social Networks: